GlassScriptPhysician profile
Vanessa Cavero Chavez
NPI 1730496076
$3,827.38
in general payments reported to CMS, 2019-2025
22 companies · $1,907 in 2025
The $1,907 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $19.15 · 2021: $158 · 2022: $278 · 2023: $240 · 2024: $835 · 2025: $1,907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,982.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $774.04 | 2022-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $590.49 | 2024-2025 | |
| Glaxosmithkline, LLC. | $526.18 | 2019-2025 | Nucala |
| Csl Behring | $339.07 | 2024-2025 | Haegarda, Hizentra, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $281.62 | 2021-2025 | Takhzyro, Cuvitru, Eohilia |
| Regeneron Healthcare Solutions, INC. | $182.81 | 2024-2025 | Dupixent |
| Alk-Abello, INC | $162.89 | 2021-2025 | Pre-Pen, Alternaria Tenuis, Timothy, Standardized |
| Amgen INC. | $156.92 | 2023-2025 | Tezspire |
| Philips North America LLC | $139.43 | 2019 | |
| Biocryst US Sales Co., LLC | $115.09 | 2024-2025 | Orladeyo |
| Ionis Pharmaceuticals, INC. | $86.76 | 2025 | Dawnzera |
| Ars Pharmaceuticals Operations, INC. | $78.49 | 2025 | Neffy |
| Pharming Healthcare, INC. | $71.32 | 2024-2025 | Ruconest |
| Greer Laboratories, INC. | $52.69 | 2025 | Oralair, Palforzia |
| Sumitomo Pharma America, INC. | $50.00 | 2023 | Rethymic |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $46.30 | 2024-2025 | Cutaquig |
| Novartis Pharmaceuticals Corporation | $42.94 | 2025 | |
| Kaleo, INC. | $37.18 | 2024 | Auvi-Q |
| Hospira, INC. | $31.86 | 2025 | |
| Genentech USA, INC. | $30.97 | 2024-2025 | Xolair |
| Lilly USA, LLC | $15.33 | 2024 | Ebglyss |
| Pfizer INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Cavero Chavez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.